Position: Home> ACHIEVEMENTS >Research

At present, our company studies and reports 5 projects (all of which are raw materials + preparations); Two of the original registered 3.1 classes, ulinastatin acetate tablets, masititan tablets and tablets, have been approved for clinical trials; Three of the original 6 classes have been registered, one of which has approved the human bioequivalence test. In the drug development process, we applied for patent protection for innovative technologies. Up to now, we have applied for 17 invention patents, among which 8 have obtained patent certificates, and the rest are under review.